Topiramate and motivational enhancement therapy for cannabis use among youth: a randomized placebo-controlled pilot study

Addiction Biology

Volumn 22, Issue 3, 2017, Pages 779-790

  Miranda, Robert ^a   Treloar, Hayley ^a   Blanchard, Alexander ^a   Justus, Alicia ^a   Monti, Peter M ^a   Chun, Thomas ^a   Swift, Robert ^a   Tidey, Jennifer W ^a   Gwaltney, Chad J ^a  

^a BROWN UNIVERSITY   (United States)

Author keywords

adolescents; cannabis use disorder; motivational enhancement therapy; topiramate

Indexed keywords

PLACEBO; TOPIRAMATE; FRUCTOSE; NEUROPROTECTIVE AGENT;

ABDOMINAL CRAMP; ABSTINENCE; ADOLESCENCE; ADOLESCENT; ADULT; ANXIETY DISORDER; ARTICLE; ATTENTION DISTURBANCE; CANNABIS ADDICTION; CANNABIS SMOKING; COMMON COLD; CONFUSION; CONTROLLED STUDY; COORDINATION DISORDER; COUGHING; DECREASED APPETITE; DEPRESSION; DIZZINESS; DOUBLE BLIND PROCEDURE; DROWSINESS; DRUG DOSE TITRATION; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HEADACHE; HUMAN; INJURY; MAJOR CLINICAL STUDY; MALE; MEMORY DISORDER; MOTIVATIONAL ENHANCEMENT THERAPY; NAUSEA; PARANASAL SINUS DISEASE; PARESTHESIA; PILOT STUDY; PSYCHOTHERAPY; RANDOMIZED CONTROLLED TRIAL; RASH; RHINORRHEA; SIDE EFFECT; SOMNOLENCE; SORE THROAT; STOMACH PAIN; TREATMENT OUTCOME; VISUAL IMPAIRMENT; ANALOGS AND DERIVATIVES; FEASIBILITY STUDY; MARIJUANA ABUSE; MOTIVATIONAL INTERVIEWING; PROCEDURES; PSYCHOLOGICAL FEEDBACK; YOUNG ADULT;

ADOLESCENT; ADULT; DOUBLE-BLIND METHOD; FEASIBILITY STUDIES; FEEDBACK, PSYCHOLOGICAL; FEMALE; FRUCTOSE; HUMANS; MALE; MARIJUANA ABUSE; MOTIVATIONAL INTERVIEWING; NEUROPROTECTIVE AGENTS; PILOT PROJECTS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84954305488     PISSN: 13556215     EISSN: 13691600     Source Type: Journal    
DOI: 10.1111/adb.12350     Document Type: Article

References (49)

1. Association AP (2000) Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, Text Revision. American Psychiatric Association: Washington, DC.
2. Bender K, Tripodi SJ, Sarteschi C, Vaughn MG (2011) A meta-analysis of interventions to reduce adolescent cannabis use. Res Social Work Prac 21:153–164.
3. Bolla KI, Brown K, Eldreth D, Tate K, Cadet JL (2002) Dose-related neurocognitive effects of marijuana use. Neurology 59:1337–1343.
4. Carpenter KM, McDowell D, Brooks DJ, Cheng WY, Levin FR (2009) A preliminary trial: double-blind comparison of nefazodone, bupropion-SR, and placebo in the treatment of cannabis dependence. Am J Addict 18:53–64.
5. Cornelius JR, Bukstein OG, Douaihy AB, Clark DB, Chung TA, Daley DC, Wood DS, Brown SJ (2010) Double-blind fluoxetine trial in comorbid MDD-CUD youth and young adults. Drug Alcohol Depend 112:39–45.
6. D'Amico EJ, Miles JN, Stern SA, Meredith LS (2008) Brief motivational interviewing for teens at risk of substance use consequences: a randomized pilot study in a primary care clinic. J Subst Abuse Treat 35:53–61.
7. Davis ML, Powers MB, Handelsman P, Medina JL, Zvolensky M, Smits JA (2015) Behavioral therapies for treatment-seeking cannabis users: a meta-analysis of randomized controlled trials. Eval Health Prof 38:94–114.
8. Degenhardt L, Lynskey M, Coffey C, Patton G (2002) 'Diagnostic orphans' among young adult cannabis users: persons who report dependence symptoms but do not meet diagnostic criteria. Drug Alcohol Depend 67:205–212.
9. Del Boca FK, Kranzler HR, Brown J, Korner PF (1996) Assessment of medication compliance in alcoholics through UV light detection of a riboflavin tracer. Alcohol Clin Exp Res 20:1412–1417.
10. Dennis M, Godley SH, Diamond G, Tims FM, Babor T, Donaldson J, Liddle H, Titus JC, Kaminer Y, Webb C, Hamilton N, Funk R (2004) The Cannabis Youth Treatment (CYT) Study: main findings from two randomized trials. J Subst Abuse Treat 27:197–213.
11. Gray KM, Carpenter MJ, Baker NL, DeSantis SM, Kryway E, Hartwell KJ, McRae-Clark AL, Brady KT (2012) A double-blind randomized controlled trial of N-acetylcysteine in cannabis-dependent adolescents. Am J Psychiatry 169:805–812.
12. Hjorthoj CR, Fohlmann A, Larsen AM, Arendt M, Nordentoft M (2012) Correlations and agreement between delta-9-tetrahydrocannabinol (THC) in blood plasma and timeline follow-back (TLFB)-assisted self-reported use of cannabis of patients with cannabis use disorder and psychotic illness attending the CapOpus randomized clinical trial. Addiction 107:1123–1131.
13. Johnson BA, Ait-Daoud N, Bowden CL, DiClemente CC, Roache JD, Lawson K, Javors MA, Ma JZ (2003) Oral topiramate for treatment of alcohol dependence: a randomised controlled trial. Lancet 361:1677–1685.
14. Johnson BA, Ait-Daoud N, Wang XQ, Penberthy JK, Javors MA, Seneviratne C, Liu L (2013) Topiramate for the treatment of cocaine addiction: a randomized clinical trial. JAMA psychiatry 70:1338–1346.
15. Johnson BA, Rosenthal N, Capece JA, Wiegand F, Mao L, Beyers K, McKay A, Ait-Daoud N, Anton RF, Ciraulo DA, Kranzler HR, Mann K, O'Malley SS, Swift RM, Topiramate for Alcoholism Advisory B, Topiramate for Alcoholism Study G (2007) Topiramate for treating alcohol dependence: a randomized controlled trial. Jama 298:1641–1651.
16. Johnson V, White HR (1995) The relationship between work-specific and generalized stress and alcohol and marijuana use. J Drug Issues 25:237–251.
17. Johnston LD, O'Malley PM, Miech RA, Bachman JG, Schulenberg JE (2015) Monitoring the Future National Results on Adolescent Drug Use: Overview of Key Findings, 2014 Mich. Institute for Social Research, the University of Michigan: Ann Arbor.
18. Kaufman AS, Kaufman NL (1990) Kaufman Brief Intelligence Test manual. American Guidance Service: Circle Pines, MN.
19. Kaufman J, Birmaher B, Brent D, Rao U, Flynn C, Moreci P, Williamson D, Ryan N (1997) Schedule for affective disorders and schizophrenia for school-age children-present and lifetime version (K-SADS-PL): initial reliability and validity data. J Am Acad Child Adolesc Psychiatry 36:980–988.
20. Knapp CM, Ciraulo DA, Sarid-Segal O, Richardson MA, Devine E, Streeter CC, Oscar-Berman M, Surprise C, Colaneri L, Putnam M, Waters M, Richambault C (2015) Zonisamide, topiramate, and levetiracetam: efficacy and neuropsychological effects in alcohol use disorders. J Clin Psychopharmacol 35:34–42.
21. Kranzler HR, Covault J, Feinn R, Armeli S, Tennen H, Arias AJ, Gelernter J, Pond T, Oncken C, Kampman KM (2014) Topiramate treatment for heavy drinkers: moderation by a GRIK1 polymorphism. Am J Psychiatry 171:445–452.
22. Levin FR, Mariani J, Brooks DJ, Pavlicova M, Nunes EV, Agosti V, Bisaga A, Sullivan MA, Carpenter KM (2013) A randomized double-blind, placebo-controlled trial of venlafaxine-extended release for co-occurring cannabis dependence and depressive disorders. Addiction 108:1084–1094.
23. Levin FR, Mariani JJ, Brooks DJ, Pavlicova M, Cheng W, Nunes EV (2011) Dronabinol for the treatment of cannabis dependence: a randomized, double-blind, placebo-controlled trial. Drug Alcohol Depend 116:142–150.
24. Levin FR, McDowell D, Evans SM, Nunes E, Akerele E, Donovan S, Vosburg SK (2004) Pharmacotherapy for marijuana dependence: a double-blind, placebo-controlled pilot study of divalproex sodium. Am J Addict 13:21–32.
25. Levine J, Schooler NR (1986) SAFTEE: a technique for the systematic assessment of side effects in clinical trials. Psychopharmacol Bull 22:343–381.
26. Mason BJ, Crean R, Goodell V, Light JM, Quello S, Shadan F, Buffkins K, Kyle M, Adusumalli M, Begovic A, Rao S (2012) A proof-of-concept randomized controlled study of gabapentin: effects on cannabis use, withdrawal and executive function deficits in cannabis-dependent adults. Neuropsychopharmacology 37:1689–1698.
27. McRae-Clark AL, Carter RE, Killeen TK, Carpenter MJ, Wahlquist AE, Simpson SA, Brady KT (2009) A placebo-controlled trial of buspirone for the treatment of marijuana dependence. Drug Alcohol Depend 105:132–138.
28. McRae-Clark AL, Carter RE, Killeen TK, Carpenter MJ, White KG, Brady KT (2010) A placebo-controlled trial of atomoxetine in marijuana-dependent individuals with attention deficit hyperactivity disorder. Am J Addic 19:481–489.
29. Miller WR, Rollnick S (2002) Motivational Interviewing: Preparing People for Change, 2nd edn. New York: Guilford Press.
30. Miranda R Jr, MacKillop J, Monti PM, Rohsenow DJ, Tidey J, Gwaltney C, Swift R, Ray L, McGeary J (2008) Effects of topiramate on urge to drink and the subjective effects of alcohol: a preliminary laboratory study. Alcohol Clin Exp Res 32:489–497.
31. Miranda R Jr, MacKillop J, Treloar H, Blanchard A, Tidey JW, Swift RM, Chun T, Rohsenow DJ, Monti PM (2014) Biobehavioral mechanisms of topiramate's effects on alcohol use: an investigation pairing laboratory and ecological momentary assessments. Addict Biol. DOI: 10.1111/adb.12912.
32. Moreira FA, Lutz B (2008) The endocannabinoid system: emotion, learning and addiction. Addict Biol 13:196–212.
33. Moyers TB, Martin T, Manuel JK, Miller WR, Ernst D (2007) Revised Global Scales: Motivational Interviewing Treatment Integrity Manual 3.0 (MITI 3.0). University of New Mexico Center on Alcoholism, Substance Abuse, and Addictions.
34. Muthén LK, Muthén BO (1998-2013) Mplus user's guide, 7th edn. Los Angeles, CA: Muthén & Muthén.
35. Norberg MM, Mackenzie J, Copeland J (2012) Quantifying cannabis use with the timeline followback approach: a psychometric evaluation. Drug Alcohol Depend 121:247–252.
36. Oncken C, Arias AJ, Feinn R, Litt M, Covault J, Sofuoglu M, Kranzler HR (2014) Topiramate for smoking cessation: a randomized, placebo-controlled pilot study. Nicotine Tob Res 16:288–296.
37. Pandina GJ, Ness S, Polverejan E, Yuen E, Eerdekens M, Bilder RM, Ford L (2010) Cognitive effects of topiramate in migraine patients aged 12 through 17 years. Pediatr Neurol 42:187–195.
38. Salinsky MC, Storzbach D, Spencer DC, Oken BS, Landry T, Dodrill CB (2005) Effects of topiramate and gabapentin on cognitive abilities in healthy volunteers. Neurology 64:792–798.
39. Samhsa (2012) Treatment Episode Data Set (TEDS): 2000-2010 National Admissions to Substance Abuse Treatment Services. DASIS Series S-61. Administration SAaMHS (ed). Substance Abuse and Mental Health Services Administration: Rockville, MD.
40. Shank RP, Gardocki JF, Streeter AJ, Maryanoff BE (2000) An overview of the preclinical aspects of topiramate: pharmacology, pharmacokinetics, and mechanism of action. Epilepsia 41:S3–9.
41. Simeone TA, Wilcox KS, White HS (2006) Subunit selectivity of topiramate modulation of heteromeric GABA(A) receptors. Neuropharmacology 50:845–857.
42. Sobell LD, Sobell MD (1992) Timeline follow-back: A technique for assessing self-reported alcohol consumption. In: Measuring Alcohol Consumption. Allen RLJ (ed). The Humana Press Inc: Totowa, NJ.
43. Solowij N, Michie PT, Fox AM (1995) Differential impairments of selective attention due to frequency and duration of cannabis use. Biol Psychiatry 37:731–739.
44. Solowij N, Stephens R, Roffman RA, Babor T (2002) Does marijuana use cause long-term cognitive deficits? Jama 287:2653–2654 author reply 2654.
45. Stephens RS, Roffman RA, Fearer SA, Williams C, Burke RS (2007) The Marijuana Check-up: promoting change in ambivalent marijuana users. Addiction 102:947–957.
46. Volkow ND, Baler RD, Compton WM, Weiss SR (2014) Adverse health effects of marijuana use. N Engl J Med 370:2219–2227.
47. Walker DD, Roffman RA, Stephens RS, Wakana K, Berghuis J, Kim W (2006) Motivational enhancement therapy for adolescent marijuana users: a preliminary randomized controlled trial. J Consult Clin Psychol 74:628–632.
48. Whittaker TA, Pituch KA, McDougall GJ Jr (2014) Latent growth modeling with domain-specific outcomes comprised of mixed response types in intervention studies. J Consult Clin Psychol 82:746–759.
49. Zeger SL, Liang KY, Albert PS (1988) Models for longitudinal data: a generalized estimating equation approach. Biometrics 44:1049–1060.